1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Dr H Barron
| |||
b)
|
Position/status
|
Chief Scientific Officer and President, R&D
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$41.8100
|
2,516.286
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume Price
| |||||
e)
|
Date of the transaction
|
2021-08-19
| |||
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Dr H Barron
| |||
b)
|
Position/status
|
Chief Scientific Officer and President, R&D
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b)
|
Nature of the transaction
|
Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$41.8100
|
64
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume Price
| |||||
e)
|
Date of the transaction
|
2021-08-19
| |||
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr J Ford
| |||
b)
|
Position/status
|
SVP & General Counsel
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$41.8100
|
62.356
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume Price
| |||||
e)
|
Date of the transaction
|
2021-08-19
| |||
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
Attachments
- Original document
- Permalink
Disclaimer
GSK - GlaxoSmithKline plc published this content on 23 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 August 2021 17:03:06 UTC.